Institute of General Practice and Family Medicine, Witten/Herdecke University, Alfred-Herrhausen-Strasse 50, 58448 Witten, Germany
National Institute for Health Research School for Primary Care Research, School of Health Sciences, University of Manchester, UK.
BMJ. 2020 Jun 18;369:m1822. doi: 10.1136/bmj.m1822.
To evaluate the effects of a computerised decision support tool for comprehensive drug review in elderly people with polypharmacy.
Pragmatic, multicentre, cluster randomised controlled trial.
359 general practices in Austria, Germany, Italy, and the United Kingdom.
3904 adults aged 75 years and older using eight or more drugs on a regular basis, recruited by their general practitioner.
A newly developed electronic decision support tool comprising a comprehensive drug review to support general practitioners in deprescribing potentially inappropriate and non-evidence based drugs. Doctors were randomly allocated to either the electronic decision support tool or to provide treatment as usual.
The primary outcome was the composite of unplanned hospital admission or death by 24 months. The key secondary outcome was reduction in the number of drugs.
3904 adults were enrolled between January and October 2015. 181 practices and 1953 participants were assigned to electronic decision support (intervention group) and 178 practices and 1951 participants to treatment as usual (control group). The primary outcome (composite of unplanned hospital admission or death by 24 months) occurred in 871 (44.6%) participants in the intervention group and 944 (48.4%) in the control group. In an intention-to-treat analysis the odds ratio of the composite outcome was 0.88 (95% confidence interval 0.73 to 1.07; P=0.19, 997 of 1953 1055 of 1951). In an analysis restricted to participants attending practice according to protocol, a difference was found favouring the intervention (odds ratio 0.82, 95% confidence interval 0.68 to 0.98; 774 of 1682 873 of 1712, P=0.03). By 24 months the number of prescribed drugs had decreased in the intervention group compared with control group (uncontrolled mean change -0.42 0.06: adjusted mean difference -0.45, 95% confidence interval -0.63 to -0.26; P<0.001).
In intention-to-treat analysis, a computerised decision support tool for comprehensive drug review of elderly people with polypharmacy showed no conclusive effects on the composite of unplanned hospital admission or death by 24 months. Nonetheless, a reduction in drugs was achieved without detriment to patient outcomes.
Current Controlled Trials ISRCTN10137559.
评估计算机决策支持工具在老年人多病用药综合药物审查中的效果。
实用、多中心、集群随机对照试验。
奥地利、德国、意大利和英国的 359 家全科诊所。
3904 名年龄在 75 岁及以上、常规使用 8 种或 8 种以上药物的成年人,由他们的全科医生招募。
一种新开发的电子决策支持工具,包括全面的药物审查,以支持全科医生减少潜在不适当和无证据支持的药物。医生被随机分配到电子决策支持工具或提供常规治疗。
主要结局是 24 个月内无计划住院或死亡的复合结局。关键次要结局是减少药物数量。
2015 年 1 月至 10 月期间共纳入 3904 名成年人。181 家诊所和 1953 名参与者被分配到电子决策支持(干预组),178 家诊所和 1951 名参与者被分配到常规治疗(对照组)。干预组 871 名(44.6%)参与者和对照组 944 名(48.4%)发生主要结局(24 个月内无计划住院或死亡的复合结局)。意向治疗分析中,复合结局的优势比为 0.88(95%置信区间 0.73 至 1.07;P=0.19,1953 名参与者中的 997 名 1951 名参与者中的 1055 名)。在根据方案参加实践的参与者的分析中,干预组结果更有利(优势比 0.82,95%置信区间 0.68 至 0.98;1682 名参与者中的 774 名 1712 名参与者中的 873 名,P=0.03)。到 24 个月时,与对照组相比,干预组的处方药数量减少(未控制的平均变化 -0.42 0.06:调整后的平均差异 -0.45,95%置信区间 -0.63 至 -0.26;P<0.001)。
意向治疗分析显示,用于老年人多病用药综合药物审查的计算机决策支持工具在 24 个月内无计划住院或死亡的复合结局方面没有明确效果。尽管如此,在不影响患者结局的情况下,药物数量有所减少。
当前对照试验 ISRCTN86141242。